Clinical Trial Update: Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a HER2-directed dendritic cell vaccine in combination with weekly paclitaxel, trastuzumab, and pertuzumab for HER2-positive …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HER2-directed dendritic cell vaccine (DC1)
• PACLITAXEL (PACLITAXEL)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: RECRUITING